Skip to main content
Premium Trial:

Request an Annual Quote

Solexa Secures $75M Equity Financing Commitment; Cash Will Help Roll Out GAS Sequencer

NEW YORK (GenomeWeb News) – Solexa has secured a committment to sell $75 million in common stock Azimuth Opportunity, the company said today.
 
Solexa said it plans to use the cash to develop and commercialize its Genome Analysis System, for working capital, and for other general corporate purposes.
 
The commitment is for two years. During the term, Solexa may sell registered shares of its common stock to Azimuth at a small discount to the market price. The timing and amount of sales will be at Solexa’s discretion, the company said.
 
Solexa shipped its first 1G Genome Analyzers to two early-access customers in late June and has said in the past that it wants to launch the instrument widely by the end of this year.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.